Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort

被引:13
|
作者
Abdullah, Laila [1 ]
Luis, Cheryl [1 ]
Paris, Daniel [1 ]
Mouzon, Benoit [1 ]
Ait-Ghezala, Ghania [1 ]
Keegan, Andrew P. [1 ]
Wang, Duolao [2 ]
Crawford, Fiona [1 ]
Mullan, Michael [1 ]
机构
[1] Roskamp Inst, Sarasota, FL 34243 USA
[2] London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England
关键词
ALZHEIMERS-DISEASE; RISK-FACTORS; APOLIPOPROTEIN-E; DEMENTIA; HEALTH; CHOLESTEROL; MEDICATIONS; PREVENTION; STATINS; NSAIDS;
D O I
10.2119/molmed.2009.00083
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent evidence suggests an association of beta-amyloid (A beta) with vascular risk factors and the medications to treat them, which could potentially obfuscate the usefulness of A beta for prediction of mild cognitive impairment (MCI) or Alzheimer disease (AD). In a subcohort from the Alzheimer's Disease Anti-inflammatory Prevention Trial (enriched for family history of AD), we investigated whether systolic blood pressure, total cholesterol, triglycerides, serum creatinine, apolipoprotein E, and use of statins and antihypertensives influenced the predictive value of serum A beta for MCI/AD during a 2-year period. We collected blood samples to quantify serum A beta from cognitively normal participants (n = 203) at baseline and ascertained the outcome of MCI/AD (n = 24) for a period of approximately 2 years, In an unadjusted model, the lowest quartile of A beta(1-42) (hazard ratio (HR) = 2.93,95% Cl (1.02-8.32), P = 0.04) and of the A beta(1-42)/A beta(1-40) ratio (HR = 353,95% CI (1.24-10.07), P = 0.02), compared with the highest quartile, predicted conversion to MCI/AD, but no impact of A beta(1-40) was observed. No relationship between nonsteroidal antiinflammatory drug interventions and A beta on MCl/AD risk was evident. Once data were adjusted for potential confounders (age, sex, and education), vascular risk factors, and the medications listed above, the lowest quartiles of A beta(1-42) (HR = 4.47,95% Cl (1.39-14.39), P = 0.01), and of the A beta(1-42/)A beta(1-40) ratio (HR 4.87,95% CI (1.50-15.87), P = 0.01) became strong predictors of conversion to MCl/AD. In this subcohort of individuals at risk for AD, the association of All with vascular risk factors and medications to treat these conditions did not interfere with All's predictive value for MCl/AD. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2009.00083
引用
收藏
页码:432 / 437
页数:6
相关论文
共 50 条
  • [1] Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort
    Laila Abdullah
    Cheryl Luis
    Daniel Paris
    Benoit Mouzon
    Ghania Ait-Ghezala
    Andrew P. Keegan
    Duolao Wang
    Fiona Crawford
    Michael Mullan
    [J]. Molecular Medicine, 2009, 15 : 432 - 437
  • [2] Olfactory Measures as Predictors of Conversion to Mild Cognitive Impairment and Alzheimer's Disease
    Wheeler, Paul Loyd
    Murphy, Claire
    [J]. BRAIN SCIENCES, 2021, 11 (11)
  • [3] Neuropsychological Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease
    Gainotti, Guido
    Quaranta, Davide
    Vita, Maria Gabriella
    Marra, Camillo
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 38 (03) : 481 - 495
  • [4] Neuropsychological predictors of conversion to probable Alzheimer disease in elderly with mild cognitive impairment
    Garcia-Herranz, Sara
    Carmen Diaz-Mardomingo, M.
    Peraita, Herminia
    [J]. JOURNAL OF NEUROPSYCHOLOGY, 2016, 10 (02) : 239 - 255
  • [5] Chemokine serum levels in mild cognitive impairment and Alzheimer's disease
    Galimberti, D.
    Fenoglio, C.
    Lovati, C.
    Venturelli, E.
    Guidi, I.
    Corra, B.
    Scalabrini, D.
    Clerici, F.
    Mariani, C.
    Bresolin, N.
    Scarpini, E.
    [J]. JOURNAL OF NEUROLOGY, 2006, 253 : 40 - 40
  • [6] Value of Serum Nonceruloplasmin Copper for Prediction of Mild Cognitive Impairment Conversion to Alzheimer Disease
    Squitti, Rosanna
    Ghidoni, Roberta
    Siotto, Mariacristina
    Ventriglia, Mariacarla
    Benussi, Luisa
    Paterlini, Anna
    Magri, Mariachiara
    Binetti, Giuliano
    Cassetta, Emanuele
    Caprara, Deborah
    Vernieri, Fabrizio
    Rossini, Paolo M.
    Pasqualetti, Patrizio
    [J]. ANNALS OF NEUROLOGY, 2014, 75 (04) : 574 - 580
  • [7] Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors
    Cui, Yue
    Liu, Bing
    Luo, Suhuai
    Zhen, Xiantong
    Fan, Ming
    Liu, Tao
    Zhu, Wanlin
    Park, Mira
    Jiang, Tianzi
    Jin, Jesse S.
    [J]. PLOS ONE, 2011, 6 (07):
  • [8] Predictors of progression from mild cognitive impairment to Alzheimer disease
    Rozzini, Luca
    Chilovi, Barbara Vicini
    Trabucchi, Marco
    Padovani, Alessandro
    [J]. NEUROLOGY, 2008, 70 (09) : 735 - 735
  • [9] Predictors of progression from mild cognitive impairment to Alzheimer disease
    Palmer, K.
    Berger, A. K.
    Monastero, R.
    Winblad, B.
    Bachman, L.
    Fratiglioni, L.
    [J]. NEUROLOGY, 2007, 68 (19) : 1596 - 1602
  • [10] Chemokine serum levels in mild cognitive impairment as Alzheimer's disease early biomarkers
    Galimberti, D.
    Fenogli, C.
    Lovati, C.
    Venturelli, E.
    Guidi, I.
    Corra, B.
    Scalabrini, D.
    Clerici, F.
    Mariani, C.
    Bresolin, N.
    Scarpini, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 31 - 32